Items Tagged ‘Renal Cancer’

February 18, 2019

FDA Approves Nivolumab and Ipilimumab Combination for Advanced Kidney Cancer

By

The Food and Drug Administration (FDA) approved the immunotherapy drugs Opdivo and Yervoy in combination as an initial, or first-line, treatment for patients with advanced kidney cancer whose disease has an intermediate or poor prognosis. This is the first immunotherapy regimen to be approved by FDA for the initial treatment of patients with kidney cancer. […]

View full entry

Tags: News, Renal Cancer


February 18, 2019

Keytruda Plus Inlyta Improves Survival Compared ot Sutent for Treatment of Advanced Kidney Cancer

By

Results from the randomized, phase III KEYNOTE-426 clinical trial show that first-line therapy with a combination of the PD-1 targeted immunotherapy Keytruda (pembrolizumab) and the VEGF-targeted tyrosine kinase inhibitor Inlyta (axitinib) improved overall survival and delayed cancer progression-free for patients with clear-cell metastatic renal cell carcinoma, compared to the current standard of care, Sutent (sunitinib). […]

View full entry

Tags: News, Renal Cancer


February 13, 2019

Personalized Vaccine to be Tested in Patients with Kidney Cancer

By

By pairing a novel personalized cancer vaccine with a more established immunotherapy drug that is administered to patients in an innovative fashion, scientists at Dana-Farber Cancer Institute are testing a first-of-its-kind strategy aimed at improving outcomes for kidney cancer patients who are at high risk of recurrence following surgery. This two-pronged approach to mobilizing a […]

View full entry

Tags: News, Renal Cancer


January 29, 2019

Personalized Vaccine to be Tested in Patients with Kidney Cancer

By

By pairing a novel personalized cancer vaccine with a more established immunotherapy drug that is administered to patients in an innovative fashion, scientists at Dana-Farber Cancer Institute are testing a first-of-its-kind strategy aimed at improving outcomes for kidney cancer patients who are at high risk of recurrence following surgery. This two-pronged approach to mobilizing a […]

View full entry

Tags: News, Renal Cancer


April 23, 2018

FDA Approves Opdivo plus Yervoy Combination for Advanced Kidney Cancer

By

CancerConnect News: The Food and Drug Administration granted approvals to Opdivo  (nivolumab) and Yervoy (ipilimumab) in combination for the treatment of intermediate or poor risk, previously untreated advanced kidney cancer (renal cell carcinoma). About Renal Cell Carcinoma Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, accounting for more than […]

View full entry

Tags: atezolizumab, Checkpoint inhibitors Keytruda, durvalumab, Imfinzi, kidney cancer, News, nivolumab, opdivo, pembrolizumab, Renal Cancer, renal cell cancer, Tecentriq


January 25, 2018

Breakthrough Therapy Designation Awarded by FDA for Lenvima and Keytruda Combination Treatment for Advanced Renal Cell Carcinoma

By

CancerConnect News: The U.S. Food and Drug Administration (FDA) has announced “Breakthrough Therapy Designation” for the multiple receptor tyrosine kinase inhibitor Lenvima® (lenvatinib) in combination with Keytruda® (pembrolizumab) for the potential treatment of patients with advanced renal cell carcinoma (RCC). About Renal Cell Carcinoma Each year in the United States, more than 61,000 people are […]

View full entry

Tags: immunotherapy, keytruda, lenvatinib, Lenvima, News, pembrolizumab, Precision Cancer Medicine, Renal Cancer, renal cell cancer


January 5, 2018

FDA Grants Approval to Cabometyx for First-Line Treatment of Advanced Renal Cell Carcinoma

By

CancerConnect News: The United States Food and Drug Administration (FDA) has approved the kinase inhibitor Cabometyx (cabozantinib) for the treatment of renal cell carcinoma (kidney cancer). The approval is for patients with advanced renal cell carcinoma who have already been treated with prior anti-angiogenic therapy.  The FDA previously approved Cabometyx in 2016 for treatment of […]

View full entry

Tags: Cabometyx, cabozantinib, kidney cancer, News, Renal Cancer, renal cell carcinoma, Sutent


November 9, 2017

Checkpoint Inhibitors Improve Outcomes of Renal Cell Cancer

By

Opdivo (nivolumab) a novel “checkpoint” inhibitor immunotherapy has been demonstrated to produce superior three year survival benefit for patients with previously treated advanced renal cell carcinoma (RCC).1 Treatment options for RCC continue to expand and are associated with improved outcomes. About Renal Cell Carcinoma Renal cell carcinoma accounts for more than 100,000 deaths worldwide each […]

View full entry

Tags: afinitor, checkpoint inhibitor, everolimus, immunotherapy, metastatic kidney cancer, News, opdivo, PD-1, Precision Cancer Medicine, Renal Cancer


March 31, 2009

Nexavar® Is Better Tolerated than Interferon in Patients with Metastatic Renal Cell Carcinoma

By

In patients with untreated renal cell cancer (RCC), Nexavar® (sorafenib) results in a similar progression-free survival (PFS) to interferon, yet patients experience greater rates of tumor shrinkage and report a better quality of life (QOL) with Nexavar than with interferon. The results of this study were published in the Journal of Clinical Oncology.1  The kidneys are […]

View full entry

Tags: Renal Cancer